ArticleScience advances2021
Multiplexed, quantitative serological profiling of COVID-19 from blood by a point-of-care test.
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Quantitative measurement of anti-interferon-gamma autoantibodies for routine laboratory implementation.iScience · 2026Article
- Article
- A Point-of-Care Test to Measure Tacrolimus Directly from Unprocessed Whole Blood.Analytical chemistry · 2026Article
- Assessing COVID-19 seroprevalence and vaccine uptake among women of reproductive-age in Zanzibar's archipelago.PLOS global public health · 2025Article
- Advancing Microfluidic Immunity Testing Systems: New Trends for Microbial Pathogen Detection.Molecules (Basel, Switzerland) · 2024Review
- Addressing Signal Drift and Screening for Detection of Biomarkers with Carbon Nanotube Transistors.ACS nano · 2024Article
- A streamlined proximity extension assay using POEGMA polymer-coated magnetic beads for enhanced protein detection.Frontiers in bioengineering and biotechnology · 2024Article
- Ultrasensitive lateral-flow assays via plasmonically active antibody-conjugated fluorescent nanoparticles.Nature biomedical engineering · 2023Article
- Environmentally Resilient Microfluidic Point-of-Care Immunoassay Enables Rapid Diagnosis of Talaromycosis.ACS sensors · 2023Article
- Engineering Innovative Interfaces for Point-of-Care Diagnostics.Current opinion in colloid & interface science · 2023Review
- Microfluidic Organ-Chips and Stem Cell Models in the Fight Against COVID-19.Circulation research · 2023Review
- CoVSense: Ultrasensitive Nucleocapsid Antigen Immunosensor for Rapid Clinical Detection of Wildtype and Variant SARS-CoV-2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- COVID-19 Diagnosis and SARS-CoV-2 Strain Identification by a Rapid, Multiplexed, Point-of-Care Antibody Microarray.Analytical chemistry · 2023Article
- Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions.Biomedical microdevices · 2023Review
- Application of microfluidic technologies on COVID-19 diagnosis and drug discovery.Acta pharmaceutica Sinica. B · 2023Review
- Article
- Association of SARS-CoV-2 nucleocapsid viral antigen and the receptor for advanced glycation end products with development of severe disease in patients presenting to the emergency department with COVID-19.Frontiers in immunology · 2023Article
- Merging microfluidics with luminescence immunoassays for urgent point-of-care diagnostics of COVID-19.Trends in analytical chemistry : TRAC · 2022Review
- An impedimetric biosensor for COVID-19 serology test and modification of sensor performance via dielectrophoresis force.Biosensors & bioelectronics · 2022Article
- A Dual-Encoded Bead-Based Immunoassay with Tunable Detection Range for COVID-19 Serum Evaluation.Angewandte Chemie (International ed. in English) · 2022Article
Corrections and comments
- Update of
Authors and funding
24 authors.
Funding
Abstract
Highly sensitive, specific, and point-of-care (POC) serological assays are an essential tool to manage coronavirus disease 2019 (COVID-19). Here, we report on a microfluidic POC test that can profile the antibody response against multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens-spike S1 (S1), nucleocapsid (N), and the receptor binding domain (RBD)-simultaneously from 60 μl of blood, plasma, or serum. We assessed the levels of antibodies in plasma samples from 31 individuals (with longitudinal sampling) with severe COVID-19, 41 healthy individuals, and 18 individuals with seasonal coronavirus infections. This POC assay achieved high sensitivity and specificity, tracked seroconversion, and showed good concordance with a live virus microneutralization assay. We can also detect a prognostic biomarker of severity, IP-10 (interferon-γ-induced protein 10), on the same chip. Because our test requires minimal user intervention and is read by a handheld detector, it can be globally deployed to combat COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.